This research provides evidence that co-mutation of FAT3 and LRP1B may be a very promising novel biomarker for screening candidates of ICIs therapy in lung adenocarcinoma and lays a preliminary foundation for subsequent further exploration. This evidence concerns the gene FAT3 and lung adenocarcinoma.